Wockhardt
Wockhardt Limited, a prominent player in the global pharmaceutical industry, is headquartered in Mumbai, India. Founded in 1960, the company has established a strong presence in key operational regions, including the United States, Europe, and emerging markets. Wockhardt is renowned for its innovative approach to healthcare, focusing on biotechnology, generics, and specialty pharmaceuticals. The company’s core products encompass a diverse range of therapeutic areas, including antibiotics, vaccines, and biopharmaceuticals, distinguished by their commitment to quality and research-driven development. Wockhardt has achieved notable milestones, such as receiving multiple FDA approvals and expanding its manufacturing capabilities across the globe. With a robust market position, Wockhardt continues to contribute significantly to the healthcare landscape, driven by its dedication to improving patient outcomes and advancing medical science.
DitchCarbon Score
How does Wockhardt's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Wockhardt's score of 40 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Wockhardt's reported carbon emissions
In 2024, Wockhardt reported total carbon emissions of approximately 66,000,000 kg CO2e, comprising 10,052,280 kg CO2e from Scope 1, 55,818,850 kg CO2e from Scope 2, and 308,710 kg CO2e from Scope 3. This marks a significant increase in emissions compared to 2023, where emissions were about 31,000,000 kg CO2e from Scope 1 and 112,712,000 kg CO2e from Scope 2, with no Scope 3 data disclosed for that year. Wockhardt has set ambitious climate commitments, aiming for a 50% reduction in absolute emissions across both Scope 1 and Scope 2 by 2030, starting from 2021 levels. This target reflects the company's proactive approach to addressing its carbon footprint and aligns with industry standards for climate action. The commitment underscores Wockhardt's dedication to sustainability and reducing its environmental impact in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 32,846,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 143,853,000 | 000,000,000 | 00,000,000 |
| Scope 3 | - | - | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Wockhardt is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
